Skye Bioscience, Inc.
SKYENASDAQHealthcareBiotechnology
Regular session
$2.0599
−$0.1801 · -8.04%
SKYE company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
25
Weakening
Sentiment
42
Mixed
Risk resilience
11
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSkye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Punit Dhillon
- Listed since
- Jan 6, 2015
- Employees
- 12
Market position
Day range
Current $2.0599
52-week range
Current $2.0599
- Open
- $2.26
- Previous close
- $2.24
- Volume
- 106.37K
- 0.27× average
- Average volume
- 399.49K
- Average daily volume
- Market cap
- 9.05M USD
- Beta
- 2.99
- Market reference 1
- 50-day average
- $4.8698
- -57.70% below average
- 200-day average
- $6.4661
- -68.14% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 24.14M USD
- P/E (TTM)
- -0.2×
- P/B (TTM)
- -20.55×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.44×
- Earnings yield
- -188.00%
- Free cash flow yield
- -144.78%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -279.29%
- Return on assets
- -197.52%
- Return on invested capital
- -286.55%
Financial health
- Debt / equity
- -0.07×
- Current ratio
- 3.3×
- Altman Z-score
- -37.73
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 723.35K USD | — | — | — | — |
| Gross profit | −723.35K USD | — | — | — | — |
| Research and development | 42.36M USD | 18.7M USD | 5.82M USD | 6.01M USD | 2.93M USD |
| Selling, general, and administrative | 15.8M USD | 17.73M USD | 7.85M USD | 6.09M USD | 4.92M USD |
| Operating expenses | 57.44M USD | 30.19M USD | 34.74M USD | 18.31M USD | 7.85M USD |
| Interest income | 1.88M USD | 3.26M USD | 99.97K USD | 19.01K USD | 3 USD |
| Interest expense | — | 967.6K USD | 906.27K USD | 663.77K USD | 767.51K USD |
| Depreciation and amortization | 723.35K USD | 298.64K USD | 124.25K USD | 115K USD | 34.13K USD |
| Operating income | −58.16M USD | −30.19M USD | −34.74M USD | −18.31M USD | −7.85M USD |
| Net income | −55.92M USD | −26.57M USD | −37.64M USD | −19.48M USD | −8.52M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 4 misses, 1 met estimate
- Average EPS surprise
- +30.35%
- 11 comparable reports
- Latest EPS result
- -0.27
- Estimate -2.04 · Beat by 86.76%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$12.00
482.55% upsideRating distribution
5 ratingsSKYE peers
ETFs holding SKYE
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research SKYEresearch.disclaimer